| ID | Sequence | Length | GC content |
|---|---|---|---|
| GCCUGCCGGGCCGCCGUCUCCGCCUGUCGCUGGCUCCGCCGGCCGCCGG… | 7227 nt | 0.4662 | |
| AGAACUCCGUGGGAGGCCCAGUAGCCAGAGCGGAAAAUGGUCACAAUUU… | 7105 nt | 0.4600 | |
| GCCUGCCGGGCCGCCGUCUCCGCCUGUCGCUGGCUCCGCCGGCCGCCGG… | 7200 nt | 0.4661 | |
| GCCUGCCGGGCCGCCGUCUCCGCCUGUCGCUGGCUCCGCCGGCCGCCGG… | 3256 nt | 0.4736 | |
| GCCUGCCGGGCCGCCGUCUCCGCCUGUCGCUGGCUCCGCCGGCCGCCGG… | 7097 nt | 0.4654 | |
| GCCUGCCGGGCCGCCGUCUCCGCCUGUCGCUGGCUCCGCCGGCCGCCGG… | 7400 nt | 0.4676 |
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Located in cytosol; nucleolus; and nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]
A longitudinal mRNA expression analysis in human post-mortem blood samples identified the ZNF641 as a transcriptional activator with a negative coefficient in a post-mortem interval (PMI) prediction model, where it was included in a down-regulated gene cluster [Antiga et al. DOI:10.1038/s41598-021-96095-z].